Company / Operating Cash Flow
Ventyx Biosciences, Inc. Operating Cash Flow History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$130.9M
FY2024
5-year range
-$166.5M / -$6.2M
FY2020-FY2024
Trend
+21.4%
vs FY2023
Sector context
#143 of 215
Health Care
What the data says
At -$131M, Ventyx Biosciences, Inc.'s operating cash flow ranks #143 of 215 in the Health Care sector. Operating Cash Flow returned to growth in FY2024 after 3 years of decline, reaching -$131M.
Based on SEC 10-K filings.
-$131M in FY2024.
Declined from -$99M to -$131M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#143 of 215 in Health CareTop 67% of 215This company -$130.9M Sector average $661.2M
▼
-119.8% below sector average
Key checks
Key Insights
- In FY2024, operating cash flow increased 21.4% year-over-year.
- Ranks #143 out of 215 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2020.
- Lowest operating cash flow in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score 3.63 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$130.9M | +21.4% |
| FY2023 | -$166.5M | -68.6% |
| FY2022 | -$98.8M | -155.6% |
| FY2021 | -$38.6M | -523.9% |
| FY2020 | -$6.2M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026